Abstract
Inflammatory bowel diseases are characterized by a chronic relapsing course, high morbidity and impaired quality of life. Their incidence is rising, and about 25% of cases are diagnosed in pediatric age. Anti-TNF-α antibodies, such as infliximab and adalimumab (ADA), are usually administered in patients refractory to conventional therapies. However, increasing evidence suggests that they can be introduced earlier in the course of the disease, especially in patients with aggressive and extensive disease since diagnosis. ADA is a fully human anti-TNF-α antibody recently approved for pediatric Crohns disease not only in patients unresponsive to infliximab, but also as a first-line anti-TNF-α therapy. In this review, we aim to summarize the current knowledge on the use of ADA in pediatric Crohns disease and to discuss open issues regarding safety as well as future perspectives.
Original language | English |
---|---|
Pages (from-to) | 963-972 |
Number of pages | 10 |
Journal | Expert Review of Clinical Immunology |
Volume | 11 |
Issue number | 9 |
DOIs | |
Publication status | Published - Sep 2 2015 |
Keywords
- Adalimumab
- anti-TNF-α antibodies
- efficacy
- inflammatory bowel disease
- pediatric Crohn's disease
- safety
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology